Credit: Labway

On September 13, 2021, Shanghai Labway Medical Laboratory Co., Ltd. (hereinafter referred to as " Labway") was listed on Shenzhen Stock Exchange (SZSE) ChiNext. Stock code: 688622. The number of new shares publicly issued this time is 48.062 million shares, the issue price is CNY4.17/share, and the opening price is CNY18.25/share.

Established in 2007, Labway is a comprehensive service provider of integrated solutions for the inspection and diagnostic industry. It provides third-party medical inspection, pathological diagnostic services, in vitro diagnostic products and other professional technical support for medical institutions. Since its establishment, the company has insisted on the innovation of business model. On the basis of "product agency + third-party inspection", it has explored an innovative service model of providing differentiated services to regional medical institutions at all levels with the core center laboratory.

Credit: Labway

Zeng Weixiong, Chairman and General Manager of Labway, stated through online speech:” Labway has been focusing on the field of inspection and diagnosis for many years, providing in vitro diagnostic products (equipment, reagents and related accessories and consumables) and professional technical support for medical institutions and scientific research institutions in worldwide range. In the field of pathological diagnosis, the company has long-term cooperation with well-known pathological brands such as Leica and DAKO. In the fields of biochemistry, immunity and clinical diagnostics, the company's long-term agency of Roche, Sysmex and other brands also have a high degree of market recognition.”